Forty Seven 2

Forty Seven, Inc. was a clinical-stage immuno-oncology biopharmaceutical company developing therapies that target cancer immune-evasion pathways, based on technology licensed from Stanford University. Its lead program, magrolimab, was a monoclonal antibody against the CD47 "don't eat me" signal, evaluated in myelodysplastic syndrome, acute myeloid leukemia, non-Hodgkin lymphoma, and solid tumors. Seeded by Lightspeed Venture Partners in 2015, the company completed an IPO in 2018 and was acquired by Gilead Sciences in 2020 for approximately $4.9 billion, becoming a wholly-owned Gilead subsidiary. As a therapeutics developer it exposes no public developer platform, API, or SDK surface; its former site (fortyseveninc.com) now redirects to gilead.com.

Forty Seven 2 is profiled on the APIs.io network. Tagged areas include Company, Biopharmaceutical, Immuno-Oncology, Healthcare, and Clinical-Stage.

🌐 Visit website 📡 Source on GitHub

5.7/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyBiopharmaceuticalImmuno-OncologyHealthcareClinical-StageAcquiredLife Sciences

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 5.7/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.0 / 20

Commercial Clarity 0.0 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/forty-seven-2: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Resources

Company 2

The organization behind the API

Website

Website

CrunchBase

CrunchBase

Source (apis.yml)

aid: forty-seven-2
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/forty-seven-2.png
name: Forty Seven 2
description: Forty Seven, Inc. was a clinical-stage immuno-oncology biopharmaceutical company developing therapies that target
  cancer immune-evasion pathways, based on technology licensed from Stanford University. Its lead program, magrolimab, was
  a monoclonal antibody against the CD47 "don't eat me" signal, evaluated in myelodysplastic syndrome, acute myeloid leukemia,
  non-Hodgkin lymphoma, and solid tumors. Seeded by Lightspeed Venture Partners in 2015, the company completed an IPO in 2018
  and was acquired by Gilead Sciences in 2020 for approximately $4.9 billion, becoming a wholly-owned Gilead subsidiary. As
  a therapeutics developer it exposes no public developer platform, API, or SDK surface; its former site (fortyseveninc.com)
  now redirects to gilead.com.
url: https://raw.githubusercontent.com/api-evangelist/forty-seven-2/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- lightspeed-venture-partners
x-tier: stub
x-tier-reason: portfolio-lead
x-status: acquired
x-status-note: Acquired by Gilead Sciences in 2020 (~$4.9B); biopharma therapeutics developer with no public API/developer
  surface. The "2" suffix is a portfolio-scraper dedup artifact.
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-20'
tags:
- Company
- Biopharmaceutical
- Immuno-Oncology
- Healthcare
- Clinical-Stage
- Acquired
- Life Sciences
apis: []
common:
- type: Website
  url: https://www.gilead.com/
- type: CrunchBase
  url: https://www.crunchbase.com/organization/forty-seven-inc
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-20'
  status: nochange
  artifacts_added: 0
  pass: local-v1